KR20070121001A - 신혈관 형성-의존성 종양 치료용 약학적 제제 - Google Patents

신혈관 형성-의존성 종양 치료용 약학적 제제 Download PDF

Info

Publication number
KR20070121001A
KR20070121001A KR1020077023861A KR20077023861A KR20070121001A KR 20070121001 A KR20070121001 A KR 20070121001A KR 1020077023861 A KR1020077023861 A KR 1020077023861A KR 20077023861 A KR20077023861 A KR 20077023861A KR 20070121001 A KR20070121001 A KR 20070121001A
Authority
KR
South Korea
Prior art keywords
treatment
oligodioxyribonucleotides
neovascularization
dependent tumors
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077023861A
Other languages
English (en)
Korean (ko)
Inventor
마시모 이아코벨리
건터 아이스너
로라 아이리스 페로
Original Assignee
젠티엄 에스피에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000336A external-priority patent/ITMI20050336A1/it
Application filed by 젠티엄 에스피에이 filed Critical 젠티엄 에스피에이
Publication of KR20070121001A publication Critical patent/KR20070121001A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020077023861A 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제 Withdrawn KR20070121001A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2005A000336 2005-03-03
IT000336A ITMI20050336A1 (it) 2005-03-03 2005-03-03 Formulazione ad attivita' anti-tumorale
US73140405P 2005-10-28 2005-10-28
US60/731,404 2005-10-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077021114A Division KR20070120954A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제

Publications (1)

Publication Number Publication Date
KR20070121001A true KR20070121001A (ko) 2007-12-26

Family

ID=36572331

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020077023861A Withdrawn KR20070121001A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제
KR1020077021114A Withdrawn KR20070120954A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제
KR1020077021110A Withdrawn KR20070120953A (ko) 2005-03-03 2006-02-27 항암활성을 갖는 제제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020077021114A Withdrawn KR20070120954A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제
KR1020077021110A Withdrawn KR20070120953A (ko) 2005-03-03 2006-02-27 항암활성을 갖는 제제

Country Status (9)

Country Link
US (2) US20080194506A1 (enExample)
EP (2) EP1853277A1 (enExample)
JP (2) JP2008531647A (enExample)
KR (3) KR20070121001A (enExample)
AU (2) AU2006222044A1 (enExample)
CA (2) CA2598613A1 (enExample)
IL (3) IL185182A0 (enExample)
MX (2) MX2007010754A (enExample)
WO (2) WO2006094917A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
US8187897B2 (en) 2008-08-19 2012-05-29 International Business Machines Corporation Fabricating product chips and die with a feature pattern that contains information relating to the product chip
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
SG11202000952PA (en) 2017-08-03 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Formulations comprising a nucleic acid in a high concentration
MX2020010689A (es) 2018-04-12 2021-01-20 Jazz Pharmaceuticals Inc Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
US20230190783A1 (en) 2020-02-28 2023-06-22 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) * 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) * 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) * 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
JP2002512508A (ja) * 1997-05-30 2002-04-23 マクギル・ユニヴァーシティ Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド
DE19740384A1 (de) * 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
US7514414B2 (en) * 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.

Also Published As

Publication number Publication date
CA2598072A1 (en) 2006-09-14
US20080194506A1 (en) 2008-08-14
AU2006222044A1 (en) 2006-09-14
EP1855697A2 (en) 2007-11-21
AU2006222045A1 (en) 2006-09-14
IL185182A0 (en) 2008-01-20
JP2008531647A (ja) 2008-08-14
JP2008531646A (ja) 2008-08-14
IL185258A0 (en) 2008-02-09
WO2006094917A3 (en) 2006-12-14
EP1853277A1 (en) 2007-11-14
KR20070120953A (ko) 2007-12-26
US20080194507A1 (en) 2008-08-14
JP5714203B2 (ja) 2015-05-07
CA2598613A1 (en) 2006-09-14
WO2006094916A1 (en) 2006-09-14
IL185258A (en) 2010-12-30
WO2006094917A2 (en) 2006-09-14
WO2006094917A8 (en) 2008-01-31
IL185181A0 (en) 2008-01-20
MX2007010754A (es) 2007-11-07
MX2007010407A (es) 2007-10-17
KR20070120954A (ko) 2007-12-26
AU2006222045B2 (en) 2011-10-20
CA2598072C (en) 2016-05-03

Similar Documents

Publication Publication Date Title
KR20070121001A (ko) 신혈관 형성-의존성 종양 치료용 약학적 제제
Yue et al. PGRN−/− TAMs-derived exosomes inhibit breast cancer cell invasion and migration and its mechanism exploration
PT1956093E (pt) Protease de clivagem do factor von willebrand (vwf)
CN102119214A (zh) 适合于癌症治疗的包含体外扩增的t淋巴细胞和血管形成抑制剂的组合物
Catani et al. Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma
KR101662845B1 (ko) Ｎｆａｔ５ 억제제를 유효성분으로 함유하는 혈관형성 관련 질환의 예방 또는 치료용 조성물
Liu et al. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice
Robl et al. Evaluation of F8-TNF-α in models of early and progressive metastatic osteosarcoma
Zhu et al. CXC motif chemokine receptor type 4 disrupts blood-brain barrier and promotes brain metastasis through activation of the PI3K/AKT pathway in lung cancer
KR102150239B1 (ko) Ｄｒｇ２ 억제제를 유효성분으로 포함하는 항암용 조성물
Van Der Elst et al. Quantitative study of liver metastases from colon cancer in rats after treatment with cyclosporine A
Ziche et al. Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants
EP1867335B1 (en) Oligodeoxyribonucleotides combined with rapamycin for treating cancer
AU2007231651B2 (en) Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
Li et al. Down-regulation of fractalkine inhibits the in vitro and in vivo angiogenesis of the hepatocellular carcinoma HepG2 cells
Cao et al. RETRACTED: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway
CN110551197B (zh) 一种微肽及癌症治疗的药物
US20090264357A1 (en) NOVEL AGENT THAT INHIBITS ANGIOGENESIS AND METASTASIS TARGETING mTOR SIGNALING PATHWAY
WO2023223022A1 (en) Method and compositions for tumorigenesis inhibition
Rollin et al. P-109 Comparative expression of RECK, MMP-2, MMP-9 and VEGFgenes in non-small cell lung cancer
Nia et al. P-110 A novel biologic classification of non-small cell lung cancer
Ireland Understanding the role of the tumour microenvironment in chemoresistance and tumour progression
JINGJING THE ROLE OF AUTOCRINE HUMAN GROWTH HORMONE IN COLORECTAL CANCER PROGRESSION
Zhao et al. CD44-specific targeted lipid nanoparticles enhance the anti-tumor efficacy of RNA therapeutics in cancer therapy
ES2263311A1 (es) Empleo del gen slug, sus productos de transcripcion o expresion, y la proteina slug en la elaboracion de una composicion farmaceutica para el tratamiento de la esterilidad masculina.

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20071017

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid